1. Home
  2. AVXL vs AVDL Comparison

AVXL vs AVDL Comparison

Compare AVXL & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVXL
  • AVDL
  • Stock Information
  • Founded
  • AVXL 2004
  • AVDL 2015
  • Country
  • AVXL United States
  • AVDL Ireland
  • Employees
  • AVXL N/A
  • AVDL N/A
  • Industry
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • AVDL Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVXL Health Care
  • AVDL Health Care
  • Exchange
  • AVXL Nasdaq
  • AVDL Nasdaq
  • Market Cap
  • AVXL 876.0M
  • AVDL 786.3M
  • IPO Year
  • AVXL N/A
  • AVDL 1996
  • Fundamental
  • Price
  • AVXL $9.21
  • AVDL $7.75
  • Analyst Decision
  • AVXL Strong Buy
  • AVDL Strong Buy
  • Analyst Count
  • AVXL 2
  • AVDL 6
  • Target Price
  • AVXL $44.00
  • AVDL $20.00
  • AVG Volume (30 Days)
  • AVXL 2.9M
  • AVDL 1.5M
  • Earning Date
  • AVXL 02-05-2025
  • AVDL 03-03-2025
  • Dividend Yield
  • AVXL N/A
  • AVDL N/A
  • EPS Growth
  • AVXL N/A
  • AVDL N/A
  • EPS
  • AVXL N/A
  • AVDL N/A
  • Revenue
  • AVXL N/A
  • AVDL $138,160,000.00
  • Revenue This Year
  • AVXL N/A
  • AVDL $523.86
  • Revenue Next Year
  • AVXL N/A
  • AVDL $70.46
  • P/E Ratio
  • AVXL N/A
  • AVDL N/A
  • Revenue Growth
  • AVXL N/A
  • AVDL 1523.50
  • 52 Week Low
  • AVXL $3.25
  • AVDL $7.39
  • 52 Week High
  • AVXL $14.44
  • AVDL $19.09
  • Technical
  • Relative Strength Index (RSI)
  • AVXL 43.28
  • AVDL 27.63
  • Support Level
  • AVXL $10.04
  • AVDL $7.39
  • Resistance Level
  • AVXL $11.68
  • AVDL $8.74
  • Average True Range (ATR)
  • AVXL 1.22
  • AVDL 0.48
  • MACD
  • AVXL -0.35
  • AVDL -0.24
  • Stochastic Oscillator
  • AVXL 4.52
  • AVDL 8.72

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.

Share on Social Networks: